Extension of Time to File SOU

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 12/31/2020. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: QZEGIO (see, http://uspto.report/TM/87814938/mark.png)
SERIAL NUMBER: 87814938

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
      Phone: 317-277-1174
      Fax: 317 276 1919
      Email: XXXX
Proposed: Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
      Phone: 317-277-1174
      Fax: 317 276 1919
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 09/11/2018.

For International Class 005:
Current identification: Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the fifth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development

Correspondence Information (current):
      John R. Rudolph
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@lilly.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rudolph_john@lilly.com

Correspondence Information (proposed):
      John R. Rudolph
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@lilly.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rudolph_john@lilly.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /John R. Rudolph/      Date Signed: 02/17/2021
Signatory's Name: John R. Rudolph
Signatory's Position: Assistant General Counsel
Signatory's Phone: 317 277 1174
Signature method: Sent to third party for signature

PAYMENT: 87814938
PAYMENT DATE: 02/17/2021

Serial Number: 87814938
Internet Transmission Date: Wed Feb 17 17:40:37 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XX-2021021717403784
5401-87814938-770abe540541efdf9db3b82786
fc9a14398f486566215cc6215a7e41d864956635
-DA-40360035-20210217160322033445